Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pesampator in CIAS
NCT02855411Phase 2Terminated
- Sponsor
- Biogen
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pesampator in schizophrenia (3 arms), sponsored by Biogen. Primary endpoints: Change From Baseline in the MATRICS Consensus Cognitive Battery Working Memory Domain at 12 weeks and Change From Baseline in the UCSD Performance Based Skills Assessment - Validation of Intermediate Measures at 12 weeks. Started Aug 2016; status: terminated.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02855411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02855411.